NASDAQ: SPRO
Spero Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for SPRO

Based on 2 analysts offering 12 month price targets for Spero Therapeutics Inc

Min Forecast
$6.00+534.25%
Avg Forecast
$6.00+534.25%
Max Forecast
$6.00+534.25%

Should I buy or sell SPRO stock?

Based on 2 analysts offering ratings for Spero Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SPRO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SPRO as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their SPRO stock forecasts and price targets.

SPRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-28
lockedlocked$00.00+00.00%2026-09-14

1 of 1

Forecast return on equity

Is SPRO forecast to generate an efficient return?

Company
N/A
Industry
32.16%
Market
164.03%

Forecast return on assets

Is SPRO forecast to generate an efficient return on assets?

Company
N/A
Industry
20.61%

SPRO earnings per share forecast

What is SPRO's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.76
Avg 2 year Forecast
-$0.40
Avg 3 year Forecast
-$1.06

SPRO revenue forecast

What is SPRO's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$284.6k-99.32%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%

SPRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRO$0.95$6.00+534.25%Strong Buy
VRCA$3.20$12.00+275.00%Buy
NORD$2.87N/AN/A
AZR$3.81$8.50+123.10%Strong Buy
XLO$7.70$16.00+107.79%Buy

Spero Therapeutics Stock Forecast FAQ

Is Spero Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SPRO) stock is to Strong Buy SPRO stock.

Out of 2 analysts, 1 (50%) are recommending SPRO as a Strong Buy, 1 (50%) are recommending SPRO as a Buy, 0 (0%) are recommending SPRO as a Hold, 0 (0%) are recommending SPRO as a Sell, and 0 (0%) are recommending SPRO as a Strong Sell.

If you're new to stock investing, here's how to buy Spero Therapeutics stock.

What is SPRO's earnings growth forecast for 2026-2028?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.95%.

Spero Therapeutics's earnings in 2026 is -$29,513,000.On average, 5 Wall Street analysts forecast SPRO's earnings for 2026 to be -$44,176,202, with the lowest SPRO earnings forecast at -$77,655,028, and the highest SPRO earnings forecast at -$17,741,564. On average, 5 Wall Street analysts forecast SPRO's earnings for 2027 to be -$23,573,848, with the lowest SPRO earnings forecast at -$55,957,300, and the highest SPRO earnings forecast at $40,989,130.

In 2028, SPRO is forecast to generate -$61,807,063 in earnings, with the lowest earnings forecast at -$59,383,257 and the highest earnings forecast at -$63,624,918.

What is SPRO's revenue growth forecast for 2026-2028?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.99%.

Spero Therapeutics's revenue in 2026 is $41,555,000.On average, 4 Wall Street analysts forecast SPRO's revenue for 2026 to be $16,580,933, with the lowest SPRO revenue forecast at $14,731,616, and the highest SPRO revenue forecast at $18,353,342. On average, 3 Wall Street analysts forecast SPRO's revenue for 2027 to be $0, with the lowest SPRO revenue forecast at $0, and the highest SPRO revenue forecast at $0.

In 2028, SPRO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SPRO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SPRO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 20.61%.

What is SPRO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SPRO price target, the average SPRO price target is $6.00, with the highest SPRO stock price forecast at $6.00 and the lowest SPRO stock price forecast at $6.00.

On average, Wall Street analysts predict that Spero Therapeutics's share price could reach $6.00 by Oct 28, 2027. The average Spero Therapeutics stock price prediction forecasts a potential upside of 534.25% from the current SPRO share price of $0.95.

What is SPRO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SPRO) Spero Therapeutics's current Earnings Per Share (EPS) is -$0.49. On average, analysts forecast that SPRO's EPS will be -$0.76 for 2026, with the lowest EPS forecast at -$1.33, and the highest EPS forecast at -$0.30. On average, analysts forecast that SPRO's EPS will be -$0.40 for 2027, with the lowest EPS forecast at -$0.96, and the highest EPS forecast at $0.70. In 2028, SPRO's EPS is forecast to hit -$1.06 (min: -$1.02, max: -$1.09).

What is SPRO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SPRO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.